title: Initial steroid hormone dose in the treatment of idiopathic sudden deafness.
abstract: OBJECTIVE
  The purpose of this study was to clarify whether higher doses of steroids improve the prognosis of idiopathic sensorineural hearing loss (ISHL) and the suitable dose of steroid hormone.
  
  
  METHODS
  The study was a retrospective statistical analysis.
  
  
  METHODS
  This study was performed at the Department of Otolaryngology, Head Neck Surgery, Kumamoto University School of Medicine.
  
  
  METHODS
  Two hundred fifty patients with ISHL were analyzed in this study. They were divided into two groups: those receiving less than a specified daily dose of steroid and those receiving a daily dose greater than or equal to the specified dose.
  
  
  METHODS
  The patients received systemic steroid therapy combined with adenosine triphosphate, vitamins, diuretics, vasodilators, hyperbaric oxygen therapy, stellate ganglion block, or volume expander.
  
  
  METHODS
  The correlation between the initial dose of steroid hormone and the improvement rate was analyzed.
  
  
  RESULTS
  Spearman's correlation coefficients and partial correlation coefficients between the initial dose and the prognosis were all significantly negative. On the other hand, the correlations between the initial dose and the prognosis were positive in the group receiving <30 mg/day, whereas they were negative in the group receiving > or =30 mg/day, although these correlations were not significant.
  
  
  CONCLUSIONS
  The general use of steroid hormone to treat ISHL is not recommended. Furthermore, if steroid hormone is used for treatment, the use of <30 mg/day of prednisolone is preferable.
authors.affiliation: Department of Otolaryngology, Head Neck Surgery, Kumamoto University School of Medicine, Japan.
authors.forename: R
authors.initials: R
authors.lastname: Minoda
authors.forename: K
authors.initials: K
authors.lastname: Masuyama
authors.forename: K
authors.initials: K
authors.lastname: Habu
authors.forename: E
authors.initials: E
authors.lastname: Yumoto
mesh_terms: D000255:Adenosine Triphosphate / Q000627:therapeutic use; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D003627:Data Interpretation, Statistical; D004232:Diuretics / Q000627:therapeutic use; D004334:Drug Administration Schedule; D005260:Female; D003639:Hearing Loss, Sudden / Q000188:drug therapy / Q000628:therapy*; D006801:Humans; D006931:Hyperbaric Oxygenation; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage / Q000627:therapeutic use*; D012189:Retrospective Studies; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000627:therapeutic use; D014815:Vitamins / Q000627:therapeutic use
chemical_list: D000893:Anti-Inflammatory Agents; D004232:Diuretics; D014665:Vasodilator Agents; D014815:Vitamins; D000255:Adenosine Triphosphate; D011241:Prednisone